JCO Precision Oncology Conversations cover art

All Episodes

JCO Precision Oncology Conversations — 69 episodes

#
Title
1

Phase II Study of Seribantumab in Tumors Harboring NRG1 Fusions

2

JCO PO Article Insights: Circulating Cancer Genome Atlas Study 5-year Outcomes

3

JCO PO Article Insights: Analytical Validation of Tumor-Informed ctDNA Assays for MRD

4

Oncotype DX Breast Recurrence Score® Results from Paired CNB & SE Specimens

5

ctDNA in Metastatic Invasive Lobular Carcinoma

6

JCO PO Article Insights: Circulating Tumor DNA in Germ Cell Tumors

7

FGFR2b Prevalence in Advanced GC: FORTITUDE-101 Prescreening

8

Palbociclib in Tumors with CDKN2A Loss or Mutation

9

FGFR3 Alteration Status and Immunotherapy in Urothelial Cancer

10

JCO PO Article Insights: Genomic Risk Classifiers in Localized Prostate Cancer

11

DLL3 and SEZ6 Expression in Neuroendocrine Carcinomas

12

Somatic Mutations of Colorectal Cancer by Birth Cohort

13

Areas of Uncertainty in Pancreatic Cancer Surveillance

14

Lynch Syndrome Mortality in the Immunotherapy Era

15

JCO PO Article Insights: A Retrospective Analysis to Identify ICI-Sensitive Populations

16

Genomic Profile of Small Cell Bladder, Lung and Urothelial Cancer

17

JCO PO Article Insights: MUC16 Directed BiTE Therapy in Epithelioid Sarcoma

18

BRCA-Altered Uterine Sarcoma Treated with PARP Inhibitors

19

JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma

20

JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma

21

JCO PO Article Insights: Real-Time Monitoring in RCC with ctDNA

22

A Position Paper on ctDNA Testing in Clinical Trials

23

JCO PO Article Insights: TMB and Real-World ICI Outcomes in Melanoma

24

Effectiveness and Cost-Effectiveness of Gene Panels in Melanoma

25

JCO PO Article Insights: Exceptional Responders with Abexinostat and Pazopanib

26

Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic Prostate Cancer

27

JCO PO Article Insights: Prognostic Artificial Intelligence Nonmetastatic Prostate Cancer

28

JCO PO Article Insights: Therapy of Infantile Midline Low-Grade Gliomas

29

Adagrasib Following Sotorasib-Related Hepatotoxicity

30

JCO PO Article Insights: ctDNA as a Prognostic Biomarker in EGC

31

Proteomics Predictor for Immunotherapy Benefit

32

Transcriptome and ctDNA Associates with Pembrolizumab Benefit

33

JCO PO Article Insights: Germline Pathogenic Variants in Renal Cell Carcinoma

34

Uptake of Aspirin Chemoprevention in Lynch Syndrome

35

JCO PO Article Insights: Talazoparib in Solid Tumors with BRCA1/2 Mutation

36

Transcriptomic Profiling of Non-Localized Prostate Cancer

37

JCO PO Article Insights: MCED Test Preferentially Detects High-Grade Prostate Cancers

38

Molecular Characteristics of Early-Onset Biliary Tract Cancer

39

JCO PO Article Insights: Publication Trends in JCO Precision Oncology

40

CCR Score to Predict ADT Benefit in Men with Prostate Cancer

41

JCO PO Article Insights: Statistical Considerations for Biomarker-Driven Oncology Clinical Trials

42

JCO PO Article Insights: Role of ctDNA in Appendiceal Cancer

43

PD-L1 Assay Concordance in Gastric Cancer

44

JCO PO Article Insights: Serial Post Operative ctDNA Predicts Poor Breast Cancer Outcome

45

Phase II Study of Erdafitinib in Tumors with FGFR Amplifications and Mutations or Fusions

46

JCO PO Article Insights: Web-Based Pretest Genetic Education for Prostate Cancer Germline Testing

47

Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment

48

JCO PO Article Insights: Microsatellite Instability as a Biomarker in Clinical Practice

49

Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy

50

JCO PO Article Insights: Prediction of Adjuvant Pertuzumab Benefit by 80-GS

51

MultiCancer Detection Test Performance in Symptomatic Individuals

52

JCO PO Article Insights: Diverse Study Samples in Clinical Trials

53

Tumor Mutational Burden and Advanced Pancreatic Cancer

54

Representativeness of Lung-MAP Participants

55

Perspectives on Universal Germline Testing for Colorectal Cancer

56

Outcomes of the IMMray PanCan-d Test in High-Risk Individuals

57

Implementation of the Maine Cancer Genomics Initiative

58

Pertuzumab + Trastuzumab in Lung Cancer with ERBB2 Alterations

59

MMR-P Colorectal Cancer in Lynch Syndrome

60

Real-World NTRK Fusions and TRK Inhibitors in Veterans

61

Larotrectinib for TRK Fusion - Positive Lung Cancer

62

ctDNA for Recurrence Prediction in Esophagogastric Cancers

63

KRAS Variants, G12C, TMB, high PD-L1 Expression in Solid Tumors

64

Universal Genetic Germline Testing in Solid Tumor Cancer Patients

65

Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma, with Dr. Shilpa Gupta

66

Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors, with Dr. Mark Stewart

67

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures with Dr. Mark Yarchoan

68

Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer with Dr. Thanh Dellinger

69

Introducing JCO Precision Oncology and Its Editor in Chief, Dr. James Ford